One To Watch

Aldeyra Therapeutics

A Nasdaq-listed clinical-stage biotechnology company developing small-molecule therapies for immune-mediated diseases. Aldeyra Therapeutics focuses on reactive aldehyde species (RASP) modulation as a differentiated approach to treating inflammatory and retinal disorders.

Company Overview

Aldeyra Therapeutics is a clinical-stage biopharmaceutical company developing therapies designed to treat immune-mediated and metabolic diseases.

The company’s strategy centers on modulation of reactive aldehyde species, a class of pro-inflammatory mediators implicated in a range of diseases. By targeting upstream drivers of inflammation, Aldeyra aims to develop therapies with broad applicability across ocular, dermatologic and systemic conditions.

The company operates as a pipeline-driven biotech with multiple late-stage programs, particularly in ophthalmology, alongside earlier-stage assets derived from its RASP platform.

Headquarters and Global Presence

headquartered in Lexington, Massachusetts, United States
conducts clinical development globally across ophthalmology and systemic disease indications

The company maintains a U.S.-centric operating structure with international clinical trial activity.

Founding and History

founded in 2004
publicly listed on Nasdaq under ticker ALDX

Aldeyra was established to develop therapies targeting inflammatory pathways, with a particular emphasis on aldehyde biology. Over time, the company has evolved toward a more focused pipeline centered on ophthalmology and immune-mediated diseases.

Recent years have included pipeline reprioritization, with discontinuation of certain assets and increased focus on next-generation RASP modulators and late-stage programs.

Therapy Areas and Focus

Aldeyra develops therapies across immune-mediated diseases.

Key areas include:

ocular diseases, including dry eye disease and allergic conjunctivitis
retinal diseases
dermatologic conditions
systemic inflammatory diseases

The company prioritizes indications where inflammation is a central driver of disease.

Technology Platforms and Modalities

The company’s platform is centered on RASP modulation.

Key components include:

small-molecule reactive aldehyde species (RASP) modulators
targeting upstream inflammatory mediators
ophthalmic, dermatologic and systemic delivery approaches

This mechanism is designed to neutralize toxic aldehydes that contribute to inflammation and tissue damage, offering a differentiated approach compared with traditional anti-inflammatory therapies.

Key Pipeline and Programs

Reproxalap

Modality: small-molecule RASP modulator (ophthalmic)
Indication focus: dry eye disease and allergic conjunctivitis
Status: Phase III and regulatory stage
Mechanism: reduction of inflammation through aldehyde modulation

ADX-2191

Modality: intravitreal methotrexate formulation
Indication focus: proliferative vitreoretinopathy and retinitis pigmentosa
Status: Phase III (with orphan designations)

ADX-248 / next-generation RASP modulators

Modality: small-molecule RASP modulators
Indication focus: retinal and systemic immune-mediated diseases
Status: preclinical and early clinical development

Additional programs

Modality: RASP modulators across ocular and systemic indications
Status: Phase II and earlier development

The pipeline reflects a mix of late-stage ophthalmology assets and earlier-stage systemic programs.

Key Personnel

Todd C. Brady, MD, PhD, President and Chief Executive Officer

The leadership team includes experience in clinical development, ophthalmology and small-molecule drug discovery.

Strategic Partnerships

Aldeyra employs a selective partnership model.

Key relationships include:

AbbVie, option agreement for reproxalap commercialization

The company primarily advances its pipeline internally while using partnerships to support commercialization and strategic flexibility.

FAQ Section

The central strategic issue is whether the RASP modulation approach can deliver consistent clinical efficacy in late-stage trials and regulatory settings. The platform’s value depends on translating a differentiated biological mechanism into approved therapies.

Reproxalap is the company’s lead and most advanced asset. Its regulatory outcome in dry eye disease represents the primary near-term value driver and a key validation point for the RASP platform.

RASP modulators target reactive aldehydes that contribute to inflammation. This upstream mechanism differs from traditional anti-inflammatory therapies that act on downstream signaling pathways.

Ocular diseases such as dry eye and allergic conjunctivitis provide well-defined clinical endpoints and regulatory pathways. These indications also allow localized drug delivery, which can improve safety and efficacy.

ADX-2191 is a late-stage retinal program with orphan designations. It provides diversification beyond reproxalap and represents a second potential commercial asset.

The company focuses on immune-mediated diseases.

Key areas include: